1. ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP. (12th June 2019) Authors: Nowakowski, G.S.; Hong, F.; Scott, D.W.; Macon, R.; King, R.L.; Habermann, T.M.; Wagner‐Johnston, N.; Casulo, C.; Wade, J.L.; Nagargoje, G.G.; Reynolds, C.M.; Cohen, J.B.; Khan, N.; Amengual, J.; Richards, K.L.; Little, R.F.; Leonard, J.P.; Friedberg, J.W.; Kostakoglu, L.; Kahl, B.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE). (June 2017) Authors: Thanarajasingam, G.; Dueck, A.C.; Novotny, P.J.; Witzig, T.E.; Habermann, T.M.; Nowakowski, G.S.; Flowers, C.R.; Bartlett, N.L.; Blum, K.A.; Pitcher, B.N.; Jung, S.; Atherton, P.J.; Tan, A.D.; Sloan, J.A.; Leonard, J.P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CLINICAL FEATURES, TREATMENT AND OUTCOME OF NEUROLYMPHOMATOSIS: SINGLE INSTITUTION EXPERIENCE. (12th June 2019) Authors: Novo, M.; Nowakowski, G.S.; Micallef, I.N.; Ristow, K.; Habermann, T.M.; Johnston, P.B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. GB VIRUS‐C (GBV‐C) INFECTION AND RISK OF LYMPHOMA: A CASE‐CONTROL STUDY FROM NORTH AMERICA. (June 2017) Authors: Fama, A.; Allmer, C.; Link, B.K.; Xiang, J.; Klinzman, D.; Feldman, A.J.; Nowakowski, G.S.; Liebow, M.; Larson, M.C.; Slager, S.L.; Call, T.G.; Habermann, T.M.; Cerhan, J.R.; Stapleton, J.T. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY. (12th June 2019) Authors: Maurer, M.J.; Jakopsen, L.H.; Habermann, T.M.; Nowakowski, G.S.; Ansell, S.M.; Thompson, C.A.; Brown, P.D.; Jørgensen, J.M.; Frederiksen, H.; Syrbu, S.; Feldman, A.L.; Novak, A.J.; Rimsza, L.M.; Cerhan, J.R.; El‐Galaly, T.C.; Link, B.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION. (12th June 2019) Authors: Novo, M.; Nowakowski, G.S.; Habermann, T.M.; Witzig, T.E.; Micallef, I.N.; Johnston, P.B.; Inwards, D.J.; Ristow, K.; Young, J.R.; Ansell, S.M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PET‐CR AS A SURROGATE FOR SURVIVAL OUTCOMES IN DLBCL: A LITERATURE BASED META‐ANALYSIS. (12th June 2019) Authors: Berry, D.A.; Broglio, K.R.; Ward, C.; Sahin, D.; Nielsen, T.; Mattiello, F.; McGlothlin, A.E.; Wendelberger, B.A.; Foster, M.; Nowakowski, G.S.; Kostakoglu, L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PHASE II STUDY OF DURVALUMAB (ANTI–PD‐L1) COMBINED WITH EITHER R‐CHOP OR LENALIDOMIDE AND R‐CHOP IN PREVIOUSLY UNTREATED, HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Jaeger, U.; Kalakonda, N.; Everaus, H.; Fustier, P.; Jaeger, J.; Manzke, O.; Nowakowski, G.S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY). (12th June 2019) Authors: Zhu, J.; Song, Y.; Smith, S.D.; O'Connor, O.A.; Luo, W.; Shazer, R.L.; Zhang, L.; Han, I.; Jivani, M.A.; Liu, Y.; Nowakowski, G.S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma. (12th June 2019) Authors: Vitolo, U.; Witzig, T.E.; Gascoyne, R.D.; Scott, D.W.; Zhang, Q.; Jurczak, W.; Özcan, M.; Hong, X.; Zhu, J.; Jin, J.; Belada, D.; Bergua, J.M.; Piazza, F.; Mócikova, H.; Molinari, A.L.; Yoon, D.H.; Cavallo, F.; Tani, M.; Izutsu, K.; Kato, K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗